Covidien : ev3 Dealogic Deal # : 686849
Data as of : 6/23/2010
Target Acquiror Dates & Values
ev3 Covidien
Target: 100 % stake Buying: 100 % stake Rumored - Deal Value $m 2,585.1
NS EVVV 113 m shares outstanding Public (Listed) Announced 1st Jun 2010 Value ex Debt $m 2,585.1
United States United States
Healthcare Healthcare Expected 3Q 2010 Consideration
JPMorgan | Advisor Morgan Stanley | Advisor Completed -
Piper Jaffray | Advisor Skadden Arps | Attorney for Advisor
Latham & Watkins | Attorney for Advisor Ropes & Gray | Attorney Withdrawn -
Oppenheimer Wolff | Attorney
Willkie Farr | Attorney Termination Fee, Target $m tbd
Termination Fee, Acquiror $m tbd
Financials 1st Apr 2010
Balance Sheet Debt/Equity: 0.2
Timeline Events Premiums & Multiples
Initial Offer $22.50
Current Offer $22.50
Income Statement
Cash Flows
Operations $m 80
Profitability
Profit Margin 8%
Return on Equity 7%
League Table Impact Sector Trend
2010 YTD Announced Global M&A by Deal Value, $bn Monthly Announced Global M&A, $bn: Healthcare
1 Goldman Sachs 215.9
2 Credit Suisse 195.2
3 Morgan Stanley 172.3
4 JPMorgan 167.8
5 BOA Merrill Lynch 159.6
6 Deutsche Bank 140.5
7 Citi 134.1
8 Barclays Capital 124.5
9 Lazard 110.8
10 UBS 105.0
2010 Dealogic. All rights reserved.